Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Sponsor
Isfahan University of Medical Sciences
Study ID
NCT04143321
Phase
PHASE4
Status
Completed

Conditions

  • Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 MG — DRUG
    after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group

Study Details

this study was aimed to evaluation of antiangial effect of a new fda drug approval on angina in diabetic patient with refractory angina

Key Dates

Start date
Sep 10, 2018
Status verified
Oct 2019
Primary completion
Apr 15, 2019
Completion
May 23, 2019

Study Design

Enrollment
75 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: empagliflozin
    following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
  • Placebo Comparator: No drug
    following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done

Primary Outcome Measure

Seattle angina questionnaire 1 [ Time Frame: 4 weeks ]

Related Studies